Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Phase 3
18–60
10 sites in AL, AZ, CA +3
About this study
This Phase 3 study is testing Frexalimab in people with multiple sclerosis.
Based on ClinicalTrials.gov records.
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
monoclonal antibody
Secondary: Medical device AEs, ADEs, SAEs, SADEs and device deficiencies throughout the study, Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs, and potentially clinically significant abnormality(PCSA) in laboratory tests, and vital signs during the study period, Pharmacokinetic parameters: Cmax(part A), Pharmacokinetic parameters: Tmax(part A)
Neurology